Evidence map›Paper›PMID 42240617›Full record

ArticleNucleic acids research2026

PARP1 trapping activates ATM-mediated NF-κB signaling independent of replication in response to TOP1 blockade.

Elodie Bournique, Ambrocio Sanchez, Kim Ha, Katrina M Yan, Lavanya Manjunath, Gisselle Santiago, Pedro Ortega, Rémi Buisson

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elodie BourniqueDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0003-0196-7996
Ambrocio SanchezDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0003-1462-1767
Kim HaDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0009-0001-6541-1375
Katrina M YanDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0009-0005-0053-5456
Lavanya ManjunathDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0003-1898-3570
Gisselle SantiagoDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0003-3601-0019
Pedro OrtegaDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0003-4216-3695
Rémi BuissonDepartment of Biological Chemistry, School of Medicine, University of California Irvine, Irvine, CA 92697, United States.ORCID 0000-0002-7196-8209

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Joel E Milam · 1994 to 2026
$57.9M
Molecular Mechanisms of APOBEC-Induced Mutagenesis in CancerR37CA252081 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2021 to 2026
$2.5M
Mechanisms and Functional Roles of PARP1 Hyperactivation in CancerR01CA307676 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2026 to 2026
$640k
NF-KB regulation by the DNA damage responseR21ES036190 · NIEHS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUISSON, REMI · 2025 to 2025
$432k
Role of APOBEC3B in the Innate Immune ResponseR21AI185033 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Remi Buisson · 2025 to 2026
$425k
American Cancer SocietyCalifornia Institute for Regenerative MedicineChao Family Comprehensive Cancer Center P30-CA062203CIRM TG2-01152EMBO ALTF 213-2023National Institutes of Health Research Supplements to Promote Diversity in Health-Related Research R37-CA252081-S1NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA307676NCI NIH HHS R37 CA252081NIAID NIH HHS R21 AI185033NIEHS NIH HHS R21 ES036190NIH HHS R21-AI185033NIH HHS R21-ES036190NIH HHS R37-CA252081NIH HHS RSG-24-1249960-01-DMCNIH HHS T32-AR080622NIH HHS T34-GM136498UCI Division of Graduate Studies
6 · The paper itself

Abstract

The NF-κB signaling pathway is a key driver of inflammation and can be activated by many genotoxic stresses. Yet, the mechanisms by which different types of DNA damage trigger NF-κB remain poorly understood. In this study, we find that NF-κB activation by topoisomerase 1 (TOP1) inhibition is strongly increased when cells are treated in combination with PARP inhibitors. Mechanistically, we demonstrate that TOP1 inhibition activates ATM-mediated NF-κB signaling through two distinct pathways: a replication-dependent pathway triggered by replication fork collapse and a replication-independent pathway revealed upon PARP1 inhibition. We further show that PARP1 enzymatic activity is not required to suppress NF-κB signaling after TOP1 inhibition during the replication-independent pathway. Instead, PARP inhibitors trap PARP1 at DNA lesions, thereby blocking repair and promoting ATM-dependent NF-κB signaling, mimicking the cell response to TDP1 depletion. These findings reveal an unexpected role for PARP1 as an NF-κB activator when trapped at DNA lesions induced by TOP1 inhibition, providing a therapeutic opportunity to use PARP inhibitors to enhance inflammatory responses and potentially improve the efficacy of TOP1-targeted cancer therapies.

Indexed as

Ataxia Telangiectasia Mutated ProteinsNF-kappa BPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesSignal TransductionTopoisomerase I InhibitorsDNA DamageDNA ReplicationDNA Topoisomerases, Type IHumansPoly(ADP-ribose) Polymerase InhibitorsAtaxia Telangiectasia Mutated ProteinsATM protein, humanDNA Topoisomerases, Type INF-kappa BPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesTOP1 protein, humanTopoisomerase I Inhibitors

Identifiers

PMID42240617
PMCPMC13234507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.